Biology subjects

Nian, C.

Publications and source records attributed to Nian, C..

4 recordsLinked to original sources

bioRxiv2023

Calcium-dependent transcriptional profiles of human pancreatic islet cells reveal functional diversity in islet subpopulations

Aims/hypothesisPancreatic islets depend on cytosolic calcium to trigger the secretion of glucoregulatory hormones and regulate the transcription of genes important for the response to stimuli. To date, there has not been an attempt to profile calcium-regulated gene expression in all islet cell types. Our aim was to construct a large single-cell transcriptomic dataset from human islets exposed to conditions that would acutely induce or inhibit intracellular calcium signalling, while preserving biological heterogeneity. MethodsWe exposed intact human islets from three donors to the following conditions: (1) 2.8 mM glucose; (2) 25 mM glucose and 40 mM KCl to maximally stimulate calcium signalling; and (3) 25 mM glucose, 40 mM KCl and 5 mM EGTA (calcium chelator) to inhibit calcium signalling, for 1 hour. We sequenced 43,909 cells from all islet cell types, and further subsetted the cells to form an endocrine cell-specific dataset of 32,486 cells expressing INS, GCG, SST or PPY. We compared transcriptomes across conditions to determine the differentially expressed calcium-regulated genes in each endocrine cell type, and in each endocrine cell subcluster of alpha and beta cells. ResultsBased on the number of calcium-regulated genes, we found that each alpha and beta cell cluster had a different magnitude of calcium response. We also showed that a polyhormonal cluster expressing INS, GCG, and SST is defined by calcium-regulated genes specific to this cluster. Finally, we identified the gene PCDH7 from the beta cell clusters that had the highest number of calcium-regulated genes, and showed that cells expressing cell surface PCDH7 protein have enhanced glucose-stimulated insulin secretory function. ConclusionsHere we use our single-cell dataset to show that human islets have cell-type-specific calcium-regulated gene expression profiles, some of them specific to subpopulations. In our dataset, we identify PCDH7 as a novel marker of beta cells having an increased number of calcium-regulated genes and enhanced insulin secretory function. Data availabilityA searchable and user-friendly format of the data in this study, specifically designed for rapid mining of single-cell RNA sequencing data, is available at https://lynnlab.shinyapps.io/Hislet_2023/. The raw data files are available at NCBI Gene Expression Omnibus (GSE196715).

physiology↗

bioRxiv2023

Tracking insulin- and glucagon-expressing bihormonal cells during differentiation using an INSULIN and GLUCAGON double reporter human embryonic stem cell line

Human embryonic stem cell (hESC)-derived pancreatic alpha and beta cells can be used to develop cell replacement therapies to treat diabetes. However, recent published differentiation protocols yield varying amounts of alpha and beta cells amidst heterogeneous cell populations. To visualize and isolate hESC-derived alpha and beta cells, we generated a GLUCAGON-2A- mScarlet and INSULIN-2A-EGFP dual fluorescent reporter (INSEGFPGCGmScarlet) hESC line using CRISPR/Cas9. We established robust expression of EGFP and mScarlet fluorescent proteins in insulin- and glucagon-expressing cells respectively without compromising the differentiation or function of these cells. We also showed the insulin- and glucagon-expressing bihormonal population at the maturing endocrine cell stage (Stage 6) lose insulin expression over time, while maintaining an alpha-like expression profile, suggesting these bihormonal cells are preferentially fated to become alpha-like cells in vitro. Together, the INSEGFPGCGmScarlet hESC line provides an efficient strategy for tracking populations of hESC-derived beta- and alpha-like cells.

developmental biology↗

bioRxiv2023

Truncated CD19 as a selection marker for the isolation of stem cell derived β-cells

Stem cell-derived {beta}-cells (SC{beta}-cell) are a renewable and scalable alternative to cadaveric islets as a cell replacement therapy for type 1 diabetes (T1D). However, heterogeneity within SC{beta}-cell cultures remains problematic for graft safety and function. Magnetic selection of SC{beta}-cells expressing a unique cell surface marker may help deplete undesirable cell types and facilitate functional maturation. Here, we explored CD19 as a potential cell surface marker for the enrichment of insulin-expressing SC{beta}-cells. Using CRISPR/Cas9 technology, we created a knock-in add-on of CD19-mScarlet downstream of the insulin coding sequence in human embryonic stem cells (hESCs). We established reproducible SC{beta}-cell surface expression of CD19-mScarlet. Importantly, we developed and optimized a magnetic sorting protocol for CD19-mScarlet-expressing cells, forming enriched SC{beta}-cell clusters with improved glucose-stimulated c-peptide secretion. This strategy holds promise to facilitate large-scale production of functional SC{beta}-cells for disease modeling and cell replacement therapy.

bioengineering↗

bioRxiv2022

Type 2 diabetes susceptibility gene GRK5 regulates physiological pancreatic β-cell proliferation via phosphorylation of HDAC5 in mice

ObjectiveDiabetes onset is accompanied with {beta}-cell deficiency, and thus restoring functional {beta}-cell mass is a promising therapy for those with diabetes. However, the regulatory mechanisms controlling {beta}-cell mass are not fully understood. Previously, we demonstrated that the transcription factor SOX4 is required for {beta}-cell proliferation in the prediabetic state. To elucidate potential mechanisms by which SOX4 regulates {beta}-cell mass, we performed RNA sequencing (RNA-seq) using pancreatic {beta}-cell specific SOX4 knockout mice ({beta}SOX4 KO). The RNA-seq revealed decreased expression of GRK5, a known type 2 diabetes susceptibility gene whose association with diabetes has not been fully elucidated. Therefore, we aimed to clarify the function of GRK5 in pancreatic {beta} cells. MethodsWe generated a novel pancreatic {beta} cell-specific GRK5 knockout mass ({beta}GRK5 KO) and evaluated glucose tolerance and metabolic changes by body weight measurement, oral glucose tolerance test, and insulin tolerance test. The number of pancreatic {beta} cells was quantified by immunohistochemistry. Glucose loading and Ca2+ imaging was performed on isolated islets to evaluate insulin secretory capacity. To elucidate the mechanism of {beta}GRK5 on {beta} cell mass regulation, we performed RNA-seq of isolated islets and identified the signaling pathways that could be regulated by GRK5. Furthermore, in vitro experiments were conducted using human islets and mouse {beta}GRK5 KO islets to clarify the direct effects of GRK5 on these pathways. Results{beta}GRK5 KO islets showed impaired glucose tolerance and insulin secretion, but no change in body weight or insulin resistance, suggesting that the main cause of impaired glucose tolerance is impaired insulin secretion. Isolated islets showed no abnormalities in insulin secretory capacity or changes in calcium influx, but histologically showed a decrease in {beta} cell mass. Consistent with the decreased {beta} cell mass in {beta}GRK5 KO, the cell cycle inhibitor gene Cdkn1a was upregulated in {beta}GRK5 KO islets; this phenocopies the {beta}SOX4 KO. Furthermore, we found that Grk5 positively regulates facultative increases in {beta} cell mass through activity-dependent phosphorylation of HDAC5 and subsequent transcription of immediate early genes (IEGs) such as Nr4a1, Fosb, Junb, Arc, Egr1 and Srf. ConclusionsOur results suggest that GRK5 is associated with type 2 diabetes through regulation of {beta} cell mass. GRK5 could become a potential target of cell therapy to preserve functional {beta} cells during the progression towards frank diabetes.

physiology↗